ERBB2 and breast carcinoma: Over 70% of breast carcinomas are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-), collectively designated as HR+/HER2-breast carcinomas (Setiawan et al., 2009; Howlader et al., 2014).